CO6460732A2 - Antagonistas del receptor de cgrp - Google Patents
Antagonistas del receptor de cgrpInfo
- Publication number
- CO6460732A2 CO6460732A2 CO12068979A CO12068979A CO6460732A2 CO 6460732 A2 CO6460732 A2 CO 6460732A2 CO 12068979 A CO12068979 A CO 12068979A CO 12068979 A CO12068979 A CO 12068979A CO 6460732 A2 CO6460732 A2 CO 6460732A2
- Authority
- CO
- Colombia
- Prior art keywords
- cgrp
- antagonists
- refers
- disclosure
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
Abstract
La divulgación se refiere a los compuestos nuevos de formula I,incluidas las sales farmacéuticamente aceptables, que son antagonistas del receptor de CGRP. La divulgación también se refiere a composiciones farmacéuticas y métodos para usar los compuestos en el tratamiento de trastornos relacionados con CGRP, incluidas migrañas y otras cefaleas, vasodilatación neurogénica, inflamación neurogénica, lesión térmica, shock circulatorio, sofocos asociados con la menopausia, enfermedades inflamatorias de las vías aéreas tales como asma, y enfermedad pulmonar obstructiva crónica (EPOC).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25147709P | 2009-10-14 | 2009-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6460732A2 true CO6460732A2 (es) | 2012-06-15 |
Family
ID=43242489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12068979A CO6460732A2 (es) | 2009-10-14 | 2012-04-26 | Antagonistas del receptor de cgrp |
Country Status (34)
Country | Link |
---|---|
US (2) | US8314117B2 (es) |
EP (1) | EP2488512B1 (es) |
JP (3) | JP5836279B2 (es) |
KR (3) | KR101755742B1 (es) |
CN (1) | CN102656159B (es) |
AR (2) | AR078638A1 (es) |
AU (1) | AU2010306954B2 (es) |
BR (1) | BR112012008828B1 (es) |
CA (2) | CA2968176C (es) |
CL (1) | CL2012000925A1 (es) |
CO (1) | CO6460732A2 (es) |
DK (1) | DK2488512T3 (es) |
EA (1) | EA020409B1 (es) |
ES (1) | ES2441192T3 (es) |
FR (1) | FR22C1044I2 (es) |
HK (1) | HK1169390A1 (es) |
HR (1) | HRP20140111T1 (es) |
HU (1) | HUS2200033I1 (es) |
IL (1) | IL219120A (es) |
LT (1) | LTPA2022516I1 (es) |
MX (1) | MX2012004182A (es) |
NL (1) | NL301187I2 (es) |
NO (1) | NO2022033I1 (es) |
NZ (1) | NZ599281A (es) |
PE (1) | PE20121137A1 (es) |
PL (1) | PL2488512T3 (es) |
PT (1) | PT2488512E (es) |
RS (1) | RS53149B (es) |
SI (1) | SI2488512T1 (es) |
SM (1) | SMT201400019B (es) |
TN (1) | TN2012000139A1 (es) |
TW (1) | TWI465448B (es) |
WO (1) | WO2011046997A1 (es) |
ZA (1) | ZA201203452B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314117B2 (en) * | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8669368B2 (en) * | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
US8748429B2 (en) * | 2011-04-12 | 2014-06-10 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
MX352171B (es) * | 2012-02-27 | 2017-11-13 | Bristol Myers Squibb Co | Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato. |
EP2846801B1 (en) * | 2012-05-09 | 2017-04-05 | Merck Sharp & Dohme Corp. | Pyridine cgrp receptor antagonists |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
TW201718574A (zh) * | 2015-08-12 | 2017-06-01 | 美國禮來大藥廠 | Cgrp受體拮抗劑 |
GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
SG11202009199YA (en) | 2018-03-25 | 2020-10-29 | Biohaven Pharm Holding Co Ltd | Rimegepant for cgrp related disorders |
CN114805206A (zh) * | 2021-01-27 | 2022-07-29 | 奥锐特药业(天津)有限公司 | 高光学纯度瑞美吉泮中间体的工业化制备方法 |
AU2022230300A1 (en) | 2021-03-02 | 2023-09-21 | Cgrp Diagnostics Gmbh | Treatment and/or reduction of occurrence of migraine |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
CN116554164A (zh) * | 2022-01-27 | 2023-08-08 | 奥锐特药业(天津)有限公司 | 一种瑞美吉泮的制备方法 |
WO2023175632A1 (en) * | 2022-03-17 | 2023-09-21 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof |
CN116478211B (zh) * | 2022-04-19 | 2023-10-24 | 石家庄迪斯凯威医药科技有限公司 | 一种新型cgrp受体拮抗剂及其用途 |
CN115060824B (zh) * | 2022-06-14 | 2024-03-12 | 浙江宏元药业股份有限公司 | 一种瑞米吉泮中间体对映异构体杂质的液相色谱检测方法 |
CN117466893A (zh) * | 2022-07-29 | 2024-01-30 | 熙源安健医药(上海)有限公司 | 吡啶并环庚烷类衍生物及其制备方法和用途 |
CN115677694A (zh) * | 2022-11-30 | 2023-02-03 | 南通常佑药业科技有限公司 | 一种瑞美吉泮的合成方法 |
CN117486798A (zh) * | 2023-12-21 | 2024-02-02 | 南京威凯尔生物医药科技有限公司 | 一种瑞美吉泮中间体盐酸盐的晶型及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
US7855294B2 (en) | 2004-03-05 | 2010-12-21 | Banyu Pharmaceutical Co., Ltd. | Cycloalkanopyridine derivative |
US8039460B2 (en) | 2004-10-13 | 2011-10-18 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
US20060084708A1 (en) | 2004-10-14 | 2006-04-20 | Bayer Materialscience Llc | Rigid foams with good insulation properties and a process for the production of such foams |
US7745427B2 (en) | 2004-10-22 | 2010-06-29 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
CA2649158A1 (en) | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Process for the preparation of pyridine heterocycle cgrp antagonist intermediate |
US8143403B2 (en) | 2008-04-11 | 2012-03-27 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8314117B2 (en) * | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
-
2010
- 2010-10-12 US US12/902,714 patent/US8314117B2/en active Active
- 2010-10-13 NZ NZ599281A patent/NZ599281A/xx unknown
- 2010-10-13 KR KR1020127012197A patent/KR101755742B1/ko active IP Right Grant
- 2010-10-13 CN CN201080056672.4A patent/CN102656159B/zh active Active
- 2010-10-13 BR BR112012008828-9A patent/BR112012008828B1/pt active IP Right Grant
- 2010-10-13 CA CA2968176A patent/CA2968176C/en active Active
- 2010-10-13 RS RS20140035A patent/RS53149B/en unknown
- 2010-10-13 MX MX2012004182A patent/MX2012004182A/es active IP Right Grant
- 2010-10-13 JP JP2012534309A patent/JP5836279B2/ja active Active
- 2010-10-13 CA CA2777518A patent/CA2777518C/en active Active
- 2010-10-13 KR KR1020187018446A patent/KR101990755B1/ko active IP Right Grant
- 2010-10-13 PE PE2012000490A patent/PE20121137A1/es active IP Right Grant
- 2010-10-13 EP EP10768347.6A patent/EP2488512B1/en active Active
- 2010-10-13 WO PCT/US2010/052433 patent/WO2011046997A1/en active Application Filing
- 2010-10-13 AU AU2010306954A patent/AU2010306954B2/en active Active
- 2010-10-13 KR KR1020177018206A patent/KR101875353B1/ko active IP Right Grant
- 2010-10-13 PT PT107683476T patent/PT2488512E/pt unknown
- 2010-10-13 SI SI201030486T patent/SI2488512T1/sl unknown
- 2010-10-13 ES ES10768347.6T patent/ES2441192T3/es active Active
- 2010-10-13 EA EA201270561A patent/EA020409B1/ru not_active IP Right Cessation
- 2010-10-13 DK DK10768347.6T patent/DK2488512T3/en active
- 2010-10-13 PL PL10768347T patent/PL2488512T3/pl unknown
- 2010-10-14 AR ARP100103755A patent/AR078638A1/es not_active Application Discontinuation
- 2010-10-14 TW TW099135091A patent/TWI465448B/zh active
-
2012
- 2012-03-28 TN TNP2012000139A patent/TN2012000139A1/en unknown
- 2012-04-05 IL IL219120A patent/IL219120A/en active IP Right Grant
- 2012-04-12 CL CL2012000925A patent/CL2012000925A1/es unknown
- 2012-04-26 CO CO12068979A patent/CO6460732A2/es unknown
- 2012-05-11 ZA ZA2012/03452A patent/ZA201203452B/en unknown
- 2012-10-08 HK HK12109845.4A patent/HK1169390A1/xx unknown
- 2012-10-16 US US13/652,690 patent/US20130053570A1/en not_active Abandoned
-
2014
- 2014-02-05 HR HRP20140111AT patent/HRP20140111T1/hr unknown
- 2014-02-17 SM SM201400019T patent/SMT201400019B/xx unknown
-
2015
- 2015-04-30 JP JP2015092727A patent/JP6109874B2/ja active Active
-
2017
- 2017-03-08 JP JP2017043761A patent/JP6258537B2/ja active Active
- 2017-11-13 AR ARP170103159A patent/AR110069A2/es not_active Application Discontinuation
-
2022
- 2022-07-14 NL NL301187C patent/NL301187I2/nl unknown
- 2022-07-18 HU HUS2200033C patent/HUS2200033I1/hu unknown
- 2022-07-22 NO NO2022033C patent/NO2022033I1/no unknown
- 2022-08-02 LT LTPA2022516C patent/LTPA2022516I1/lt unknown
- 2022-08-11 FR FR22C1044C patent/FR22C1044I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6460732A2 (es) | Antagonistas del receptor de cgrp | |
CY1122121T1 (el) | N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας | |
WO2009126530A3 (en) | Piperidine derivatives as cgrp receptor antagonists | |
AR080746A1 (es) | (r)-n-(3-(7-metil-1h-indazol-5-il)1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida antagonista de receptores cgrp. | |
AR048343A1 (es) | Agentes terapeuticos para el tratamiento de la migrana | |
ECSP16054826A (es) | Derivados Novedosos de Amino Pirimidina | |
CO2019008986A2 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
ECSP088741A (es) | Derivados de benzotriazol como agonistas del adrenoreceptor beta2 | |
DOP2016000175A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
UY29167A1 (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
GT200900289A (es) | Compuestos organicos.- | |
GT201500218A (es) | Compuesto | |
CR20140516A (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
WO2007130860A3 (en) | Constrained compounds as cgrp-receptor antagonists | |
AR049384A1 (es) | Derivados de purina | |
WO2007130927A3 (en) | Condensed tricyclic compounds as cgrp-receptor antagonists | |
NO20084564L (no) | Stramme "Constrained" forbindelser som CGRP-reseptor antagonister | |
CY1114902T1 (el) | Ανταγωνιστες cgrp υποδοχεα | |
CO6331339A2 (es) | Derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
TH134920B (th) | Cgrp รีเซปเตอร์แอนตาโกนิสต์ | |
CU20100217A7 (es) | Derivados de quinuclidina como antagonistas de receptores muscarínicos m3 | |
TH149198B (th) | Cgrp รีเซพเตอร์ แอนทากอนิสต์ | |
UA107820C2 (en) | Antagonists receptor ccr2 and their use |